Abstract:There is growing evidence that estrogen receptors (ER) are expressed in lung cancer cells, and are able to interact with the epidermal growth factor receptor (EGFR) signaling pathway. However, data on the association between cytoplasmic ER expression and the response to EGFR-tyrosine kinase inhibitors (TKI) treatment are limited. The aim of the present study was to investigate the associations between ERα/ERβ expression and EGFR mutational status and response to TKI treatment in metastatic lung adenocarcinoma. A retrospective study of 126 consecutive patients with lung adenocarcinoma who were diagnosed with stage IV disease and had received EGFR-TKI treatment was conducted. ER expression was detected by immunohistochemistry. EGFR and GTPase KRas (KRAS) mutational statuses were evaluated by denaturing high performance liquid chromatography and PCR-restriction fragment length polymorphism, respectively. In the overall cohort of 126 lung adenocarcinoma samples analyzed, ERα expression in the nucleus of tumor cells was identified in 17 (18.9%) patients, whereas ERβ expression was identified in the nucleus (22/126, 17.5%) and cytoplasm (17/126, 13.5%). The nuclear expression of ERβ was positively associated with the degree of tumor differentiation (P=0.010). EGFR-sensitizing mutations were significantly associated with improved objective response rates (ORR), disease control rates (DCR), median progression-free survival (mPFS) and median overall survival (mOS) (P<0.001; P<0.001; P=0.003; and P=0.026, respectively). Patients with cytoplasmic ERβ expression exhibited non-significant poorer ORR, DCR, mPFS and mOS compared with patients without cytoplasmic ERβ expression (P=0.082; P=0.106; P=0.084; and P=0.119, respectively). However, the significant decrease of ORR, DCR and mPFS was observed in patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations (P=0.030; P=0.009; and P=0.018, respectively) in comparison with the subgroup with EGFR sensitizing mutations but negative expression of cytoplasmic ERβ. A trend towards shorter mOS was also observed in patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations (P=0.071). No KRAS mutations were identified in patients with cytoplasmic ERβ expression. Subsequent to adjusting for sex, smoking status and EGFR mutation status, the Cox repression analysis indicated that cytoplasmic expression of ERβ was a negative independent predictor for mPFS in the whole patient cohort (HR=1.870; 95% confidence interval 1.058-3.305; P=0.031). Cytoplasmic ERβ expression was negatively correlated with the efficacy of EGFR-TKI treatment for metastatic lung adenocarcinoma, particularly for patients with coexisting cytoplasmic ERβ expression and EGFR-sensitizing mutations. Cytoplasmic ERβ may be a promising marker to predict the outcome of EGFR-TKI treatment.

Cytoplasmic Expression of G Protein-Coupled Estrogen Receptor 1 Correlates with Poor Postoperative Prognosis in Non-Small Cell Lung Cancer

Estrogen-Related Receptor Α (errα) and G Protein-Coupled Estrogen Receptor (GPER) Synergistically Indicate Poor Prognosis in Patients with Triple-Negative Breast Cancer

Double-edged Role of G Protein-Coupled Estrogen Receptor 1 in Breast Cancer Prognosis: an Analysis of 167 Breast Cancer Samples and Online Data Sets

Downregulation of G Protein-Coupled Estrogen Receptor (GPER) is Associated with Reduced Prognosis in Patients with Gastric Cancer

G Protein-Coupled Estrogen Receptor (GPER) Mediates NSCLC Progression Induced by 17Β-Estradiol (E 2 ) and Selective Agonist G1

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma

The expression of estrogen receptors β2, 5 identifies and is associated with Prognosis in non-small cell lung cancer

Expression of GPER in endometrioid adenocarcinoma and correlation between GPER expression level and ER

High GPER Expression in Triple-Negative Breast Cancer is Linked to Pro-Metastatic Pathways and Predicts Poor Patient Outcomes

The Expression Of Estrogen Receptors Beta 2, 5 Identifies And Is Associated With Prognosis In Non-Small Cell Lung Cancer

G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen

Prognostic Role of GPER/Ezrin in Triple-Negative Breast Cancer is Associated with Menopausal Status.

G Protein-Coupled Estrogen Receptor 1 (GPER 1) Mediates Estrogen-Induced, Proliferation of Leiomyoma Cells.

Cytoplasmic ERß Expression to Predict Efficacy and Survival of EGFR-TKI in EGFR-mutant NSCLC.

Overexpression of Estrogen Receptor Beta is A Prognostic Marker in Non-Small Cell Lung Cancer: A Meta-Analysis

Expression of ERCC1 in the Patients with Non-Small-cell Lung Cancer

G Protein-Coupled Oestrogen Receptor Promotes Cell Growth Of Non-Small Cell Lung Cancer Cells Via Yap1/Qki/Circnotch1/M6a Methylated Notch1 Signalling

High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.

Function of G-Protein-Coupled Estrogen Receptor-1 in Reproductive System Tumors

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

Cytoplasmic Expression of Estrogen Receptor Β May Predict Poor Outcome of EGFR-TKI Therapy in Metastatic Lung Adenocarcinoma.